Loading market dashboard
Metagenomi, Inc. Common Stock
MGXHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK,
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. We would handle the matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
EMERYVILLE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D.
Metagenomi Therapeutics (MGX) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $0.68 per share a year ago.
On track for regulatory submission of MGX-001 to advance global clinical program, including investigational new drug application (“IND”) in 4Q 2026 Publication in Nature Structural & Molecular Biology highlights potential of MG119-28, a proprietary compact CRISPR nuclease with enhanced genome editing efficiency $140.2 million in cash, cash equivalents, and available-for-sale marketable securities as of March 31, 2026, with runway anticipated to support operations through 4Q 2027 EMERYVILLE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today reported financial results for the first quarter ended March 31, 2026, and provided business updates.
Metagenomi, Inc. (NASDAQ: MGX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the five research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the
Metagenomi Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Editing Efficiency
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. We would handle the matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Metagenomi (NASDAQ: MGX - Get Free Report) is expected to be issuing its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.6059) per share and revenue of $7.3270 million for the quarter. Investors are encouraged to explore the company's upcoming Q4 2025 earning overview page
Shares of Metagenomi, Inc. (NASDAQ: MGX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating
